← Back to dashboard
ResMed logo

RMDResMed

Pharma & Healthcare · US · ResMed Inc.

4 of 6 ratios computed · receipts verified server-side

Idiot Index
38
out of 100 · 4/6 ratios · FY 2023

The full receipt

Latest published value for each ratio, with the sector median for context and year-over-year change where the prior year is available.

  • Markup →

    How much revenue per dollar of cost.

    2.3545× revenue / costverified
    $1 of cost becomes $2.35 of revenue
    Sector median: 3.1882Median range for extraction in sector
    FY 2023v1.0.0
  • Operational Markup →

    Revenue per dollar of cost + operating expenses. The multiplier after legitimate operations.

    1.3941× revenue / (cost + opex)verified
    $1 of cost+opex becomes $1.39 of revenue
    Sector median: 1.2871Median range for extraction in sector
    FY 2023v1.0.0
  • Labor Share →

    How much of every revenue dollar reaches workers.

    Not computed: missing input.
    Needed but not in this company's XBRL filings: Total Employee Compensation.
    What this company did disclose: Cost of Goods Sold, Dividends Paid, Total Employee Count, Net Income, Operating Expenses, R&D Expense, Revenue
  • Executive Extraction →

    How many times a CEO out-earns the median employee.

    Not computed: missing inputs.
    Needed but not in this company's XBRL filings: CEO Total Compensation, Median Employee Compensation.
    What this company did disclose: Cost of Goods Sold, Dividends Paid, Total Employee Count, Net Income, Operating Expenses, R&D Expense, Revenue
  • Shareholder Extraction →

    Dollars sent to shareholders for every dollar invested in R&D.

    1.0063× buybacks+dividends / R&Dverified
    $1.01 to shareholders for every $1 in R&D
    Sector median: 0.7492Median range for extraction in sector
    FY 2023v1.0.0
  • Capital Extraction →

    How much of net profit goes to shareholders rather than back into the business.

    0.4778× buybacks+dividends / net incomeverified
    48% of net profit returned to shareholders, 52% reinvested
    Sector median: 0.5294Median range for extraction in sector
    FY 2023v1.0.0

Company response

No verified response yet. If you represent ResMed, you can add context, agree, or dispute.

Source data

Every raw line item this company disclosed in its XBRL filings. Click any filing to view the original on SEC.gov.

FY 2023· 7 facts
ConceptValueUnitPeriodFilingReceipt
Cost of Goods Sold
CostOfGoodsAndServicesSold
1,357,725,000USDFY0000943819-23-000011verified
Dividends Paid
PaymentsOfDividends
226,713,000USDFY0000943819-23-000011verified
Net Income
NetIncomeLoss
474,505,000USDFY0000943819-23-000011verified
Operating Expenses
OperatingExpenses
935,422,000USDFY0000943819-23-000011verified
R&D Expense
ResearchAndDevelopmentExpense
225,284,000USDFY0000943819-23-000011verified
Revenue
RevenueFromContractWithCustomerExcludingAssessedTax
3,196,825,000USDFY0000943819-23-000011verified
Total Employee Count
TotalEmployees
10,140employeesFY0000943819-23-000011verified